Could Eli Lilly (NYSE:LLY) Become the First $10 Trillion Stock?

<p>Emmet turns this week&#39;s episode into a guessing game, teasing five clues before revealing a 150-year-old company that&#39;s become one of the most important businesses in the world: Eli Lilly (NYSE:LLY). </p><p>Founded in Indianapolis in 1876, Lilly introduced the world&#39;s first commercially available insulin in 1923, pioneered recombinant DNA medicine with Humulin in 1982, and brought the world Prozac in 1986. </p><p>Today it&#39;s a $1.1 trillion company, and both Bill Mann and Porter Stansberry have separately pitched it as a candidate to become the world&#39;s first $10 trillion business. </p><p>Emmet breaks down why: Mounjaro and Zepbound drove Q2 2026 revenue up 48 percent to $23 billion, the obesity drug market may address a global population the World Health Organization estimates at 890 million adults, and Lilly&#39;s new oral pill Foundayo (orforglipron) just added a convenient alternative to injections. He also covers the experimental triple-agonist drug Retatrutide, Lilly&#39;s $5.6 billion Houston manufacturing buildout, and the math behind what a true ten-x over 20 years would actually require.</p><p>This months following Prophet, spotlighting this month&#39;s standout addition to the model portfolio, Ross Stores.</p><p>Stocks Mentioned</p><p>Eli Lilly and Company (NYSE:LLY) </p><p>Ross Stores, Inc. (NASDAQ:ROST) </p><p><br></p><p>At MyWallSt, we believe great investing is about patience, discipline, and owning outstanding businesses. Our team researches global stocks, publishes transparent performance, and helps investors build long-term wealth without hype or guesswork. Horizon is our long-term buy-and-hold service, while Prophet is a five-minutes-a-month system that has trounced the average market returns over 17 years.</p><p><br></p><p>#MyWallSt #StockClub #EliLilly #LLY #GLP1 #WeightLossDrugs #TrillionDollarStock #Pharma #StockPicks <br></p>